- AddressUniversity of NSW
Philip Barter is currently President of the International Atherosclerosis Society. He graduated in medicine from the University of Adelaide and gained his PhD from the Australian National University. He has held positions in research institutes and universities in Australia and the US and is currently based at the University of New South Wales in Australia. He is a fellow of the Royal Australasian College of Physicians. His basic research interests are plasma lipids and lipoproteins, specifically high density lipoproteins, the factors that regulate them and the mechanism by which they protect against cardiovascular disease. His clinical research involves participation in clinical trials of lipid-lowering agents. He was a member of the steering committees of the FIELD study, the TNT Study, was co-chair of steering committee of the DEFINE study and was chairman of the steering committee of the ILLUMINATE trial. He is currently a member of the steering committees of the REVEAL HPS-3 TIMI-55 trial and the ACCELERATE trial. He has published more than 350 peer-reviewed research papers on plasma lipids and lipoproteins, their metabolism, regulation, function and relationship to atherosclerosis. He has also written handbooks on HDL and CETP inhibitors.